Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux for VTE Prophylaxis in High Risk Trauma Patients
NCT00531843Phase 3Completed
- Start
- Dec 2007
- Primary completion
- Jun 2008
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, open-label trial of fondaparinux in venous thromboembolism (VTE). Primary endpoint: Presence of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE) at 3 weeks. Started Dec 2007; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00531843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531843.